The mechanisms by which SAzymes remodel the TME and enhance cancer immunotherapy are summarized, discussing recent advances in atomic level design principles and multimodal synergistic therapy.
Abstract
Tumor immunotherapy has emerged as a transformative strategy for cancer treatment. However, its clinical efficacy remains limited by the immunosuppressive tumor microenvironment (TME), which restricts immune cells infiltration, suppresses effector cells activity, and promotes immune escape. Recent advances in catalytic nanomedicine have highlighted single‐atom nanozymes (SAzymes) as a promising platform for overcoming these barriers. Owing to their atomic precision and tunable electronic structure, SAzymes exhibit highly efficient enzyme‐like catalytic activities and enable precise regulation of the TME. Through catalytic therapy, SAzymes can alleviate hypoxia, regulate lactate accumulation, disrupt redox homeostasis, and reprogram immunosuppressive immune cells populations. Importantly, SAzyme‐mediated catalytic therapy can induce immunogenic cell death (ICD), thereby enhancing antitumor immune responses. In addition, the well‐defined atomic architecture of SAzymes provides a unique opportunity to establish quantitative structure–activity relationships (QSAR), enabling rational optimization of catalytic performance through modulation of their composition and coordination environment. This review systematically summarizes the mechanisms by which SAzymes remodel the TME and enhance cancer immunotherapy, discussing recent advances in atomic level design principles and multimodal synergistic therapy. Finally, current challenges and future perspectives, including machine learning‐guided SAzymes design, biosafety and clinical translation, are discussed to guide the next generation of SAzyme‐based catalytic immunotherapies.
This review systematically summarizes recent advances in nanozyme-mediated regulation of the TME and aims to provide a theoretical basis and research perspectives for the further study, rational design, and translational application of nanozymes in cancer therapy.
Xin-Yang Zhang, Zi-Qi Wang, Yang Niu et al.· Biomaterials Research· 0 citations
Tumor catalytic therapy (TCT), an emerging therapeutic modality, exerts specific cytotoxic effects on tumor cells by catalyzing endogenous substances within the tumor microenvironment (TME)—including hydrogen peroxide (H
2
O
2
), glucose, and glutathione—to generate reactive oxygen species (ROS) or deplete prot...
You-Yu Wang, Shu-Wei Zhang, Yang-Ke He et al.· Rare Metals· 0 citations
Piezoelectric nanozymes offer a versatile platform for multimodal cancer therapy and represent a promising paradigm for developing strategies for precise, non-invasive cancer therapy through localized ROS generation and modulation of the TME.
Akanksha Deshwal, A. Vimal, Prachi Nirwan et al.· Cancer nanotechnology· 0 citations
Gold nanocomposites have evolved from passive delivery vehicles into versatile immunomodulators for cancer therapy. However, their clinical utility remains constrained by biological instability and potential toxicity. This review elucidates strategies to overcome these biological barriers through precise engineering of...
Hydrogen is employed as a therapeutic gas in the treatment of stroke, tissue repair, and cancer, owing to its excellent biocompatibility, antioxidant properties, anti-inflammatory effects, and regulation of cellular metabolism. Moreover, nanometallic materials generate hydrogen through pH-responsive, light-responsive,...
Yuxuan Ding, Min Ma, Jia-Ning Wang et al.· Molecules· 0 citations
Cancer immunotherapy has produced substantial clinical benefit, yet its efficacy remains limited in patients with immunologically "cold" tumors, which are characterized by poor T-cell infiltration and a suppressive tumor microenvironment (TME). Strategies for converting cold tumors into immunologically "hot" phenotypes...
Qi-Chao Yang, Li-Xuan Xu, Meng-Meng Cao et al.· Chemical Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.